These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Increase of vulnerability to lymphotoxin in cells infected by vesicular stomatitis virus and its further augmentation by interferon. Aderka D; Novick D; Hahn T; Fischer DG; Wallach D Cell Immunol; 1985 May; 92(2):218-25. PubMed ID: 2986852 [TBL] [Abstract][Full Text] [Related]
48. Primary amines enhance the antiviral activity of interferon against a membrane virus: role of intracellular pH. Maheshwari RK; Sidhu GS; Bhartiya D; Friedman RM J Gen Virol; 1991 Sep; 72 ( Pt 9)():2143-52. PubMed ID: 1654374 [TBL] [Abstract][Full Text] [Related]
49. Human monocytes and lymphocytes produce different mixtures of alpha-interferon subtypes. Goren T; Fischer DG; Rubinstein M J Interferon Res; 1986 Aug; 6(4):323-9. PubMed ID: 3772176 [TBL] [Abstract][Full Text] [Related]
50. Localization of a receptor nonapeptide with a possible role in the binding of the type I interferons. Eid P; Langer JA; Bailly G; Lejealle R; Guymarho J; Tovey MG Eur Cytokine Netw; 2000 Dec; 11(4):560-73. PubMed ID: 11125298 [TBL] [Abstract][Full Text] [Related]
51. Mechanism of interferon action. Interferon alpha inhibits vesicular stomatitis virus primary transcript accumulation in P1/eIF-2 alpha protein kinase-deficient human fibroblast cells. Zhang XT; Samuel CE J Biol Regul Homeost Agents; 1987; 1(4):157-65. PubMed ID: 2845723 [TBL] [Abstract][Full Text] [Related]
52. Selective suppression of human papilloma virus type 18 mRNA level in HeLa cells by interferon. Nawa A; Nishiyama Y; Yamamoto N; Maeno K; Goto S; Tomoda Y Biochem Biophys Res Commun; 1990 Jul; 170(2):793-9. PubMed ID: 1696477 [TBL] [Abstract][Full Text] [Related]
53. [Effect of natural and recombinant interferons on the development of an antiviral state and on the activity of natural killers]. Kuznetsov VP; Avdeev GI; Viadro MM; Leĭkin IuD; Frolova IS Dokl Akad Nauk SSSR; 1985; 284(6):1514-6. PubMed ID: 3002740 [No Abstract] [Full Text] [Related]
54. Enhancement of neutralizing efficacy by combining three monoclonal antibodies to human interferon-alpha. Kontsek P; Borecký L; Novák M; Kontseková E; Máciková I Immunology; 1991 May; 73(1):8-11. PubMed ID: 1710604 [TBL] [Abstract][Full Text] [Related]
55. Mechanism of interferon action. Inhibition of vesicular stomatitis virus in human amnion U cells by cloned human leukocyte interferon. Masters PS; Samuel CE Biochem Biophys Res Commun; 1984 Feb; 119(1):326-34. PubMed ID: 6322781 [TBL] [Abstract][Full Text] [Related]
56. [On the joint effect of interferon and histone on the cytopathic effect of vesicular stomatitis virus]. Balandin IG; Diuĭsalieva RG; Kol'tsov VD; Lushnikov AA Vopr Virusol; 1968; 13(5):630. PubMed ID: 4303598 [No Abstract] [Full Text] [Related]
57. Influence of interferons alpha I1 and gamma and of tumour necrosis factor on persistent infection with bovine viral diarrhoea virus in vitro. Bielefeldt Ohmann H; Babiuk LA J Gen Virol; 1988 Jun; 69 ( Pt 6)():1399-403. PubMed ID: 2838577 [TBL] [Abstract][Full Text] [Related]
58. Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta. Meager A; Das RG J Immunol Methods; 2005 Nov; 306(1-2):1-15. PubMed ID: 16226271 [TBL] [Abstract][Full Text] [Related]
59. Interferon-induced resistance to the killing by NK cells: a preferential effect of IFN-gamma. Wallach D Cell Immunol; 1983 Feb; 75(2):390-5. PubMed ID: 6403252 [TBL] [Abstract][Full Text] [Related]
60. Antiviral activity of bovine interferons on primate cells. Tovey MG; Bandu MT; Begon-Lours J; Brouty-Boyé D; Gresser I J Gen Virol; 1977 Aug; 36(2):341-4. PubMed ID: 197203 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]